В кратких клинических рекомендациях представлен перечень наиболее актуальных сведений о новой коронавирусной инфекции COVID-19. Он разработан рабочей группой, созда...нной при губернаторе Санкт-Петербурга, в состав которой вошли эксперты — акушеры-гинекологи, анестезиологи-реаниматологи, клинические фармакологи, кардиологи, организаторы здравоохранения, в качестве информационного ресурса для специалистов, работающих в сфере охраны материнства и детства.
Краткие клинические рекомендации предназначены врачам — акушерам-гинекологам, анестезиологам-реаниматологам, врачам скорой медицинской помощи и другим специалистам, работающим в области оказания медицинской помощи беременным, роженицам и родильницам в Санкт-Петербурге и Северо-Западном федеральном округе, а также клиническим ординаторам.
more
Этот документ, содержащий ответы на часто задаваемые вопросы, дополняет временные рекомендации ВОЗ «Клиническое руководство по ведению пациентов с тяжелой остро... респираторной инфекцией при подозрении на инфицирование новым коронавирусом» и посвящен вопросам в связи с этими рекомендациями.
Во временных рекомендациях и настоящем документе отражены:
i. имеющиеся сведения в отношении риска заражения COVID19 через грудное молоко;
ii. сведения о благотворном воздействии грудного вскармливания и контакта «кожа к коже»;
iii. сведения о неблагоприятном воздействии детских молочных смесей в случае неправильного
использования.
COVID-19 and breastfeeding (frequently asked questions)
more
This document provides an overview of the 7 main messages contained in the World malaria report 2021
The purpose of this guide is to offer recommendations for improving the implementation of non‑pharmacological public health measures during the COVID-19 response and compliance with these measures by population groups in situations of vulnerability. This requires determining the main barriers to i...mplementing these measures so that we can identify the groups and territories most affected during the different phases of the pandemic. With this objective in mind––and within the framework of an equity, human rights, and diversity approach––, policies, strategies, and interventions to accompany the implementation and flexibilization of the measures are recommended to ensure that no one is left behind.
more
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
Every year, nearly 250 million people move across borders temporarily or permanently for a job opportunity, studying, to flee a crisis back home, or for other reasons. Another 750 million move for similar reasons within the borders of their countries. With the understanding that human mobility affec...ts public health, and health affects human mobility and migrants, for decades, IOM has been providing critical health services to women, children and men on the move, while standing by governments for technical and operational support as needed. In 2019, in lower-income settings and in complex emergencies, along the world’s most perilous migration routes, in the aftermath of natural disasters or in response to disease outbreaks, IOM’s health teams have provided hundreds of thousands with primary health-care consultations, mental health and psychosocial support, sexual and reproductive health care, pre-migration health services, and much more.
This year, more than ever before, as the world reels from the socioeconomic impact of COVID-19, we have experienced that health is a cross-cutting component of overall human development and well-being.
more
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...y of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
Calls for greater implementation research (IR) capacity came in the wake of compelling evidence that implementation strategies are critically important for the dissemination and facilitation of evidence-informed policies and interventions to tackle noncommunicable diseases (NCDs), thereby improving ...outcomes for both individuals and populations. However, at present, implementation of evidence-based interventions and policies is challenged by a gap in lack of academic research on how these cost–effective recommended interventions can be implemented in the context of local settings, especially those of low and middle-income.
more
The Country Readiness and Delivery(CRD) workstream which is part of the ACT Accelerator and is included in the SPRP– has developed a toolbox with guidance, tools and training.
Mehrsprachige Aufklärung zu Symptomen und Prävention
Bebilderte Informationsbroschüre zum Coronavirus mit Symptomen, vorbeugenden Maßnahmen, Infektion und Quarantäne sowie Hände waschen.
Ideal für die Beratungssituation und zum Verteilen in Gemeinschaftsunterkünften. Aufgrund der dynamisch...en Lage wird die Broschüre schrittweise angepasst. Eine einzige Broschüre für alle Bundesländer gleichermaßen passend ist leider nicht möglich. Tippen Sie im Gespräch auf die Begriffe, die für Sie gerade am passendsten sind.
Sprachen: Deutsch, Albanisch, Arabisch, Bulgarisch, Englisch, Farsi, Französisch, Kurdisch, Polnisch, Rumänisch, Russisch, Serbisch, Tigrinya und Türkisch
more
“Preferred product characteristics” (PPCs) are key tools to incentivize and guide the development of urgently needed health products. Some of the vector control interventions deployed in complex emergencies and in response to natural disasters – namely insecticide-treated nets (ITNs) and indoo...r residual spraying (IRS) – have already met identified public health needs in more stable settings; other tools such as insecticide-treated tarpaulins have been specifically designed for this use case. Given the diverse mix of existing and potential new interventions and the considerable gaps in the associated evidence base, this PPC aims to clearly articulate the unmet public health needs for tools designed to control malaria transmission in complex emergencies and in response to natural disasters.
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es...timate the effects of specific anti-IL-6 therapies.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
N Engl J Med 2019;380:2429-39.DOI: 10.1056/NEJMoa1901113
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are a critical tool in the battl...e against COVID-19, and getting vaccinated is one of the best ways to protect yourself and others from COVID-19.
more
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Countries around the world are rolling ou...t COVID-19 vaccines, and a key topic of interest is their safety. Vaccine safety is one of WHO’s highest priorities, and we’re working closely with national authorities to develop and implement standards to ensure that COVID-19 vaccines are safe and effective.
more